News
![NeuroSense says ALS drug extends survival](/sites/default/files/styles/x_large/public/2024-07/NeuroSense_Tx.jpg?itok=JJEb-Ax5)
NeuroSense says ALS drug extends survival
NeuroSense Therapeutics is currently facing de-listing from the Nasdaq, so encouraging data from a phase 2b trial of its PrimeC drug candidate for amyotrophic lateral sclerosis (ALS) comes